The 2026 IPO market is telling a complicated story. A review of recently priced public offerings — spanning late summer through late September — shows a market that is rewarding some new listings handsomely while punishing others sharply. The range of outcomes across this class of IPOs is striking, and it illustrates just how unpredictable the debut of a new public company can be.
**A Tale of Extremes**
At the top of the recent performance table sits Roze AI (RZAI), which priced on September 28 and has returned nearly 149% from its IPO price. That kind of gain draws attention, though it also raises questions about how the offering was initially priced relative to investor demand. On the opposite end, Advasa Holdings (ADBT), which priced in late August, has shed nearly 99% of its value — now trading at just $0.14 per share. TurboGen (TRBG) and First Breach (FBDT) have also lost the vast majority of their value since listing, down roughly 63% and 87% respectively.
These extremes are not unusual in the IPO space, but the breadth of outcomes in this particular window is notable.
**Mid-Sized Deals Showing Steadier Results**
Among companies that raised more substantial sums, performance has been more measured. ADARx Pharmaceuticals (ADRX), which raised $446 million and priced on September 24, is up about 7.4% from its offer price. American Savings Bank (ASBH), a smaller deal at $129 million, has gained 9.4% since its mid-September debut. BlossomHill Therapeutics (BLSM) is up more than 23% after raising $150 million in early August, and Vogenx (VOGX) has climbed over 40% after an $81 million offering.
These results suggest that deals with real institutional backing and meaningful deal sizes are, on average, holding up better than the smaller or undisclosed-size offerings — though this is far from a universal rule.
**The Underperformers**
Several listings have struggled considerably. Electra Therapeutics (ETRA), which raised $350 million in a September 17 offering, is down nearly 31% from its IPO price. Orion180 Insurance (OIG), which also priced on September 17 with a $240 million deal, has fallen more than 21%. Lyntris (LYNX) is off about 27% after raising $298 million in August, and Londian Wason (FOIL) has dropped more than 26% since its August listing.
Biotech and healthcare names appear in both the winner and loser columns, reflecting the well-known binary nature of investing in that space — outcomes often hinge on clinical data, regulatory decisions, or shifting investor appetite for early-stage risk.
**What Shapes an IPO's Performance?**
A few fundamental factors typically influence how a newly public company trades in its early weeks and months.
Company fundamentals matter enormously. Strong revenue growth, a clear path to profitability, and a defensible business model make a company more appealing to institutional investors who anchor the order book. When those fundamentals are thin or unproven, post-IPO volatility tends to be higher.
Peer valuations also play a central role. Underwriters typically price an IPO relative to comparable public companies, and investors often expect a discount to those peers to compensate for the added risk of owning a stock with no public track record. When that discount is too narrow — or when market sentiment shifts after pricing — new listings can quickly fall below their offer price.
Market conditions at the time of listing carry significant weight as well. A rising broader market tends to support investor appetite for new issues, while a pullback can leave recently priced deals exposed. Sentiment around a particular sector — whether enthusiasm for AI, caution around biotech, or skepticism toward insurance tech — can accelerate gains or losses independent of a company's own merits.
Finally, investor sentiment more broadly, including how the most recent IPOs have performed, creates a feedback loop. Strong returns from high-profile recent listings can pull more buyers into new offerings. A run of disappointments can do the opposite.
**What the 2026 Class Suggests**
Looking across the recent data, the 2026 IPO class so far reflects a market that is selective rather than uniformly enthusiastic. Larger, better-known deals in sectors with clear demand — like AI and biopharmaceuticals with strong data — appear to be finding buyers. Smaller deals, particularly those with undisclosed or minimal deal sizes, are faring far worse, with several essentially wiping out early investors.
For anyone watching the IPO market, the current picture reinforces a longstanding principle: going public is not a guaranteed path to a rising stock price, and the distance between the best and worst performers in any given period can be enormous.
The pipeline of upcoming listings and how this autumn class ultimately settles will be worth watching as the year draws to a close.